New antiadipogenic drugs to reduce fibroadipogenic precursor cell differentiation process in DMD

MRC · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

September 29, 2026
Response Due
Active
Status

Opportunity Overview

Muscle degeneration in Duchenne muscular dystrophy (DMD) is characterized by loss of muscle fibers and its replacement by fat and fibrotic tissue. Fibro-adipogenic progenitors (FAPs), a type of skeletal muscle resident mesenchymal stem cells, are the main cause of fibro-fatty expansion. The molecular pathways driving the differentiation of human FAPs to adipocytes remain unexplored. Recent studies have highlighted the role of Wnt/Hedgehog/Notch pathway in the regulation of FAP differentiation to adipocytes and can be promising targets to mitigate the detrimental effects of intramuscular fat infiltrations in muscular dystrophies.
This project focus to unravel and target the molecular pathways that are differentially modulated in DMD FAPs compared to control FAPs. Based on the preliminary screening of 187 small molecules from the Wnt/Hedgehog/Notch compound library previously performed in our lab, I hypothesise that the shortlisted molecules, Bruceine D, RGB (free base) and GSK 3-inhibitor 1, can effectively decrease FAPs proliferation and differentiation into adipogenic lineage, thereby reducing the degenerative process of fibro-fatty infiltration in muscular dystrophies.
The key objectives of the study are:
- To identify antiadipogenic drugs that can efficiently reverse FAPs adipogenic differentiation process in vitro and in vivo
- To identify the effect of candidate drugs on epigenetic factors in vitro
- To identify the molecular mechanism underlying the antiadipogenic effect of candidate drugs in vitro
Accomplishing these aims will allow us to identify effective therapies that could be used to reduce fibro-fatty infiltration in patients with DMD and will provide new insights into molecular and epigenetic regulation of FAPs differentiation to adipocytes.

The project aligns with many of the priorities of the BBSRC. The project will help to understand the process of muscle degeneration that takes place in patients with muscular dystrophies using human cells...

This is one of 1,833 active United Kingdom Research Development opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyMRC
CountryUnited Kingdom
CategoryResearch Development
PublishedSeptember 30, 2022
Procurement stageActive solicitation
Response dueSeptember 29, 2026
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 10, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Related Opportunities in United Kingdom

Allogeneic Chondroprogenitor Therapy (Phase II) (ACT2)
Identifying neural biomarkers and mechanisms of visual snow syndrome: advancing therapeutic targets for intervention
Exploring the differences in the structural characterisation of inhibitor binding between cryo- and room-temperature using multicrystal X-ray crystall
Disorders of attention, awareness and cognitive control
Motivational Brain Circuits for Behavioural Flexibility
Dectin-1-mediated suppression of protective anti-mycobacterial immunity
Mobile electroencephalography & computational modelling to understand the role of sleep in disease progression in amnestic mild cognitive impairment
Understanding Patient Data (UPD)

See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Research Development intelligence report in your inbox

A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.